FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136775453> ?p ?o ?g. }

• W2136775453 endingPage "R221" @default.
• W2136775453 startingPage "R221" @default.
• W2136775453 abstract "The human monoclonal antibody adalimumab is known to induce an anti-globulin response in some adalimumab-treated patients. Antibodies against adalimumab (AAA) are associated with non-response to treatment. Immunoglobulins, such as adalimumab, carry allotypes which represent slight differences in the amino acid sequences of the constant chains of an IgG molecule. Immunoglobulins with particular IgG (Gm) allotypes are racially distributed and could be immunogenic for individuals who do not express these allotypes. Therefore, we investigated whether a mismatch in IgG allotypes between adalimumab and IgG in adalimumab-treated patients is associated with the development of AAA. This cohort study consisted of 250 adalimumab-treated rheumatoid arthritis (RA) patients. IgG allotypes were determined for adalimumab and for all patients. Anti-idiotype antibodies against adalimumab were measured with a regular radio immunoassay (RIA), and a newly developed bridging enzyme linked immunosorbent assay (ELISA) was used to measure anti-allotype antibodies against adalimumab. The association between AAA and the G1m3 and the G1m17 allotypes was determined. For differences between groups we used the independent or paired samples t-test, Mann-Whitney test or Chi square/Fisher's exact test as appropriate. To investigate the influence of confounders on the presence or absence of AAA a multiple logistic regression-analysis was used. Adalimumab carries the G1m17 allotype. No anti-allotype antibodies against adalimumab were detected. Thirty-nine out of 249 patients had anti-idiotype antibodies against adalimumab (16%). IgG allotypes of RA patients were associated with the frequency of AAA: patients homozygous for G1m17 had the highest frequency of AAA (41%), patients homozygous for G1m3 the lowest frequency (10%), and heterozygous patients' AAA frequency was 14% (P = 0.0001). An allotype mismatch between adalimumab and IgG in adalimumab-treated patients did not lead to a higher frequency of AAA. On the contrary, patients who carried the same IgG allotype as present on the adalimumab IgG molecule, had the highest frequency of anti-adalimumab antibodies compared to patients whose IgG allotype differed from adalimumab. This suggests that the allotype of adalimumab may not be highly immunogenic. Furthermore, patients carrying the G1m17-allotype might be more prone to antibody responses." @default.
• W2136775453 created "2016-06-24" @default.
• W2136775453 creator A5001616446 @default.
• W2136775453 creator A5010554672 @default.
• W2136775453 creator A5012564728 @default.
• W2136775453 creator A5027069639 @default.
• W2136775453 creator A5029733252 @default.
• W2136775453 creator A5058198903 @default.
• W2136775453 creator A5067384016 @default.
• W2136775453 creator A5072691604 @default.
• W2136775453 creator A5085213730 @default.
• W2136775453 creator A5090033299 @default.
• W2136775453 creator A5090448389 @default.
• W2136775453 date "2010-01-01" @default.
• W2136775453 modified "2023-10-06" @default.
• W2136775453 title "Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study" @default.
• W2136775453 cites W1520693665 @default.
• W2136775453 cites W1969587346 @default.
• W2136775453 cites W1975033484 @default.
• W2136775453 cites W1992628263 @default.
• W2136775453 cites W2017883234 @default.
• W2136775453 cites W2026368825 @default.
• W2136775453 cites W2086552186 @default.
• W2136775453 cites W2094960644 @default.
• W2136775453 cites W2100736304 @default.
• W2136775453 cites W2107456633 @default.
• W2136775453 cites W2119046820 @default.
• W2136775453 cites W2152348310 @default.
• W2136775453 cites W2166771071 @default.
• W2136775453 cites W2168841149 @default.
• W2136775453 cites W2272291172 @default.
• W2136775453 cites W2406701327 @default.
• W2136775453 cites W2795449522 @default.
• W2136775453 cites W46650105 @default.
• W2136775453 doi "https://doi.org/10.1186/ar3208" @default.
• W2136775453 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3046534" @default.
• W2136775453 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21187010" @default.
• W2136775453 hasPublicationYear "2010" @default.
• W2136775453 type Work @default.
• W2136775453 sameAs 2136775453 @default.
• W2136775453 citedByCount "59" @default.
• W2136775453 countsByYear W21367754532012 @default.
• W2136775453 countsByYear W21367754532013 @default.
• W2136775453 countsByYear W21367754532014 @default.
• W2136775453 countsByYear W21367754532015 @default.
• W2136775453 countsByYear W21367754532016 @default.
• W2136775453 countsByYear W21367754532017 @default.
• W2136775453 countsByYear W21367754532018 @default.
• W2136775453 countsByYear W21367754532019 @default.
• W2136775453 countsByYear W21367754532020 @default.
• W2136775453 countsByYear W21367754532021 @default.
• W2136775453 countsByYear W21367754532022 @default.
• W2136775453 countsByYear W21367754532023 @default.
• W2136775453 crossrefType "journal-article" @default.
• W2136775453 hasAuthorship W2136775453A5001616446 @default.
• W2136775453 hasAuthorship W2136775453A5010554672 @default.
• W2136775453 hasAuthorship W2136775453A5012564728 @default.
• W2136775453 hasAuthorship W2136775453A5027069639 @default.
• W2136775453 hasAuthorship W2136775453A5029733252 @default.
• W2136775453 hasAuthorship W2136775453A5058198903 @default.
• W2136775453 hasAuthorship W2136775453A5067384016 @default.
• W2136775453 hasAuthorship W2136775453A5072691604 @default.
• W2136775453 hasAuthorship W2136775453A5085213730 @default.
• W2136775453 hasAuthorship W2136775453A5090033299 @default.
• W2136775453 hasAuthorship W2136775453A5090448389 @default.
• W2136775453 hasBestOaLocation W21367754531 @default.
• W2136775453 hasConcept C126322002 @default.
• W2136775453 hasConcept C159654299 @default.
• W2136775453 hasConcept C191093355 @default.
• W2136775453 hasConcept C203014093 @default.
• W2136775453 hasConcept C2777575956 @default.
• W2136775453 hasConcept C2780132546 @default.
• W2136775453 hasConcept C2780889450 @default.
• W2136775453 hasConcept C71924100 @default.
• W2136775453 hasConceptScore W2136775453C126322002 @default.
• W2136775453 hasConceptScore W2136775453C159654299 @default.
• W2136775453 hasConceptScore W2136775453C191093355 @default.
• W2136775453 hasConceptScore W2136775453C203014093 @default.
• W2136775453 hasConceptScore W2136775453C2777575956 @default.
• W2136775453 hasConceptScore W2136775453C2780132546 @default.
• W2136775453 hasConceptScore W2136775453C2780889450 @default.
• W2136775453 hasConceptScore W2136775453C71924100 @default.
• W2136775453 hasIssue "6" @default.
• W2136775453 hasLocation W21367754531 @default.
• W2136775453 hasLocation W21367754532 @default.
• W2136775453 hasLocation W21367754533 @default.
• W2136775453 hasLocation W21367754534 @default.
• W2136775453 hasLocation W21367754535 @default.
• W2136775453 hasOpenAccess W2136775453 @default.
• W2136775453 hasPrimaryLocation W21367754531 @default.
• W2136775453 hasRelatedWork W1494588691 @default.
• W2136775453 hasRelatedWork W1995051199 @default.
• W2136775453 hasRelatedWork W1998707480 @default.
• W2136775453 hasRelatedWork W2039101337 @default.
• W2136775453 hasRelatedWork W2056840912 @default.
• W2136775453 hasRelatedWork W2074027111 @default.
• W2136775453 hasRelatedWork W2136775453 @default.
• W2136775453 hasRelatedWork W2316822442 @default.

• next